The role of surgery following incomplete response to high-dose IL-2 (HD IL-2)
نویسندگان
چکیده
منابع مشابه
The role of surgery following incomplete response to high-dose IL-2 (HD IL-2)
Background Surgical resection of metastatic cancer is beneficial in select patients with cancer. HD IL-2 is an FDA approved immunotherapy for the treatment of patients with melanoma or renal cell carcinoma. IL-2 induces a complete response (CR) in 4-10% of patients while an additional 10% of patients have a partial response (PR). While not frequently reported, our experience suggests an additio...
متن کاملA retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
BACKGROUND High dose interleukin-2 (HD IL-2) can induce durable responses in a subset of patients leading to long-term survival. Immune checkpoint blockade (ICB) has demonstrated similarly durable responses in a larger proportion of patients. However, not all patients respond to immune checkpoint blockade and subsequent therapeutic options need to be explored. METHODS The PROCLAIM database wa...
متن کاملStable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
Patients with stable disease (SD) following cancer treatment have traditionally not been considered responders. We, and others, have previously shown that SD is an important response criteria in cancer patients treated with HD IL-2 immunotherapy [1-5]. Here we summarize findings from 13 sites, including 97 mRCC and 170 mM patients enrolled in the retrospective cohort of a national HD IL-2 datab...
متن کاملComplete metastasectomy after high-dose interleukin-2 (HD IL-2) therapy for melanoma
Methods A retrospective chart review was performed on patients with metastatic melanoma seen at Saint Louis University from January 1999-June 2011 who were partial responders to HD IL-2 therapy (720,000 IU/kg per dose intravenously; 14 doses, 2 cycles per course, maximum 2 courses). Survival estimates for patients that were able to undergo complete metastasectomy after HD IL-2 were compared to ...
متن کاملWhole Tumor Cell Vaccine Adjuvants: Comparing IL-12 to IL-2 and IL-15
Cancer immunotherapy (passive or active) involves treatments which promote the ability of the immune system to fight tumor cells. Several types of immunotherapeutic agents, such as monoclonal antibodies, immune checkpoint inhibitors, non-specific immunomodulatory agents, and cancer vaccines are currently under intensive investigation in preclinical and clinical trials. Cancer vaccines induce pe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal for ImmunoTherapy of Cancer
سال: 2013
ISSN: 2051-1426
DOI: 10.1186/2051-1426-1-s1-p145